Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Regeneron Pharmaceuticals (REGN)

1K + Investors. Track Smart Money conviction in REGN. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -62
Streak
1Q ▼
Buyers last Q
45%

Smart Money Signals — REGN

Based on 1340 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their REGN positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (96% of max)

96% of all-time peak
1,340 hedge funds hold REGN right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +13% more funds vs a year ago

fund count last 6Q
+153 new funds entered over the past year (+13% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 45% buying

624 buying749 selling
Last quarter: 749 funds reduced or exited vs 624 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
⚠️

Fewer new buyers each quarter (-14 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 175 → 277 → 149 → 135. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

67% of holders stayed for 2+ years

■ 67% conviction (2yr+) ■ 17% medium ■ 16% new
892 out of 1,340 hedge funds have held REGN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +119%, value -11%

Value
-11%
Shares
+118%
Last quarter: funds added +119% more shares while total portfolio value only changed -11%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📊

Peak discovery — momentum slowing

137 → 175 → 277 → 149 → 135 new funds/Q
New funds entering each quarter: 175 → 277 → 149 → 135. REGN is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 70% veterans vs 20% newcomers

■ 70% veterans ■ 10% 1-2yr ■ 20% new
Entry-cohort mix of 1,390 holders: 973 (70%) are 2+ year veterans, 138 entered 1–2 years ago, and 279 (20%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 63% AUM from top-100 funds

63% from top-100 AUM funds
69 of 1332 holders are among the 100 largest funds by AUM, controlling 63% of total institutional value in REGN. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — REGN

In 2026 Q2, 624 hedge funds were net buyers of REGN (135 opened a new position, 489 added to an existing one), while 749 reduced or exited (552 trimmed, 197 sold completely) — a 45% buyer ratio, indicating roughly balanced activity. 63% of total institutional value in REGN is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -62 funds (more exits than new entries). Total institutional holders: 1340.

Hedge Fund Ownership: REGN

How many hedge funds hold REGN — quarterly history vs. share price
Quarterly hedge fund ownership of REGN vs. share price

Market Analysis: REGN

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: REGN

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Regeneron Pharmaceuticals (REGN) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much REGN has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 78d ago
REGN
+27.3%
XLV
+5.7%

REGN outperformed XLV by +21.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 33d ago
REGN
-1.1%
XLV
+0.2%

Since the filing became public, REGN outperformed XLV by -1.3% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Broad Consensus, Selective Conviction

Many quality funds hold this stock, but top-tier positions remain relatively small.

42 top-rated funds 15 high-conviction
Consensus
7.1
/ 10
breadth
×
Elite
3.7
/ 10
conviction
Hedge Fund Positioning: REGN
1K + Investors

Track Smart Money conviction in REGN. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 1324 1402 -5.56%
13F Shares 94M 87M 7.18%
Total Value $56.98B $64.35B -11.46%
New Positions 132 149 -17
Increased Positions 475 564 -89
Closed Positions 202 129 +73
Reduced Positions 533 460 +73
Total Calls 28 32 -12.5%
Total Puts 26 30 -13.33%
PUT/CALL Ratio 0.93 0.94 Neutral

Statistics: REGN

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

1K + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in REGN. Verified SEC 13F-HR filings.

QUARTER:
Top 25 REGN holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Bronte Capital Management Pty Ltd. 10.89% 162,618 $101.4M
2 Pavaki Capital Management LLC 10.54% 19,400 $15.0M
3 Davern Capital Partners, LP 9.85% 92,640 $57.8M
4 Mcdonald Capital Investors Inc/Ca 8.79% 193,038 $120.4M
5 Orion Investment Co 5.37% 29,501 $18.4M
6 Southeastern Asset Management Inc/Tn/ 4.95% 152,322 $95.0M
7 Bronte Capital Management Pty Ltd. 4.59% 68,600 $42.8M
8 Jia Investment Alliance PTE. LTD. 3.91% 67,300 $42.0M
9 Encore Global Management, LP 3.09% 5,050 $3.1M
10 Ellerson Group Inc /Adv 3.05% 8,282 $5.2M
11 Bellecapital International Ltd. 2.75% 27,594 $17.2M
12 Noesis Capital Mangement Corp 2.49% 33,201 $20.7M
13 Evergreen Wealth Management, LLC 2.48% 8,485 $5.3M
14 Sound Shore Management Inc /Ct/ 2.44% 126,994 $79.2M
15 Peak Wealth Management LLC 2.18% 4,992 $3.1M
16 Tamar Securities, LLC 2.16% 37,102 $23.1M
17 Sector Gamma As 2.13% 15,780 $9.8M
18 Ranmore Fund Management Ltd 2.07% 30,000 $18.7M
19 Bellevue Group AG 2.06% 157,291 $98.1M
20 Sio Capital Management, LLC 1.86% 18,000 $11.2M
21 Seizert Capital Partners, LLC 1.83% 71,169 $44.4M
22 North Point Portfolio Managers Corp/Oh 1.69% 16,403 $10.2M
23 AIMZ Investment Advisors, LLC 1.63% 9,491 $5.9M
24 Cutter & CO Brokerage, Inc. 1.63% 10,838 $6.9M
25 Rhenman & Partners Asset Management AB 1.61% 27,390 $17.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Regeneron Pharmaceuticals (REGN)

What does the Smart Money Trend signal show for REGN?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their REGN positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for REGN?

More sellers than buyers — 45% buying: Last quarter: 749 funds reduced or exited vs 624 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for REGN holders?

Elite ownership — 63% AUM from top-100 funds: 69 of 1332 holders are among the 100 largest funds by AUM, controlling 63% of total institutional value in REGN. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held REGN?

67% of holders stayed for 2+ years: 892 out of 1,340 hedge funds have held REGN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Regeneron Pharmaceuticals (REGN) following the 2026 Q2 hedge fund 13F filings?

As of today, REGN has moved -1.1% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.2% for the XLV sector ETF — an outperformance of -1.3%. Since the quarter end (June 30, 2026), REGN has gained +27.3% vs +5.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →